ClinicalTrials.gg
CompletedNCT04901195BE HEARD EXTUpdated Oct 6, 2026

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 interventional study of Bimekizumab in Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL. Completed at 145 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Results publication addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
658
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
6th of 139
658 · median 45
Started
2021
with 13 others
Phase 3
24 of 161
3 open now
Registered
74th of 161
by date
Lead sponsor
6 of 161
UCB Biopharma SRL

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 6th largest by enrollment of the 139 interventional ones that give a count, is one of 14 that started in 2021, is one of 24 in phase 3, and was the 74th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Bimekizumab
  • UCB4940
  • HS
  • Hidradenitis Suppurativa
  • Acne inversa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant has completed the Maintenance Treatment Period through Week 48 in HS0003 (NCT04242446) or HS0004 (NCT04242498), was eligible to receive bimekizumab at the time of completing the feeder study, and did not meet any withdrawal criteria of the feeder study
  • Study participant is considered reliable and capable of adhering to the protocol (eg, able to understand and complete questionnaires), visit schedule, and medication intake according to the judgement of the Investigator
  • A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to follow the guidance during the open-label extension period and for at least 20 weeks after the final dose of medicinal product (IMP)

Exclusion criteria

Exclusion Criteria:

  • Female study participant who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of medicinal product (IMP)
  • Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments Note: For any study participant with an ongoing serious adverse event (SAE) from HS0003 (NCT04242446) or HS0004 (NCT04242498), or any current sign or symptom that may indicate a medically significant active infection (except for the common cold) or has had an infection requiring systemic antibiotics within 2 weeks of study entry or a history of serious infections in HS0003 or HS0004, the Medical Monitor must be consulted prior to the study participant's entry into HS0005, although the decision on whether to enroll the participant remains with the Investigator.
  • Study participant has a positive or indeterminate interferon-gamma release assay (IGRA) in a feeder study, unless appropriately evaluated and treated
  • Study participant has ongoing or planned use of prohibited hidradenitis suppurativa (HS) or non-HS treatment
  • Study participant plans to participate in another study of a medicinal product or device under investigation during this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
658 participants (actual)

Study arms

  • Experimental
    Bimekizumab dosing regimen 1

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosing regimen 2

    Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.

    Drug: Bimekizumab

Interventions

  • Subjects will receive bimekizumab at pre-specified time-points.

    Also known as: UCB4940

06

What researchers measure

Primary outcomes

  1. Percentage of participants with treatment-emergent adverse events (TEAEs) during the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.

    Time frame: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)

Secondary outcomes

  1. Percentage of participants with treatment-emergent serious adverse events (SAEs) during the study

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Important medical events

    Time frame: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)

  2. Percentage of participants with treatment-emergent adverse events (TEAEs) leading to withdrawal from the study

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported.

    Time frame: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)

  3. Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)

    HiSCR50 is defined as at least a 50 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Results will be presented individually per week listed under time points.

    Time frame: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180

  4. Percentage of participants achieving clinical response as measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)

    HiSCR75 is defined as at least a 75 % reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Results will be presented individually per week listed under time points.

    Time frame: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180

  5. Percentage of participants with Flare

    Flare is defined as a ≥25 % increase in abscess and inflammatory nodule (AN) count with an absolute increase in AN count of ≥2 relative to Baseline. Results will be presented individually per week listed under time points.

    Time frame: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180

  6. Hidradenitis Suppurativa Symptom Questionnaire (HSSQ) Response for Worst Pain

    The 4 items on the HSSQ assess the study participant's perception of the core symptoms of HS experienced in the past 7 days - pain, smell or odor, drainage or oozing from HS lesions, and itch on an 11-point numeric rating scale with higher scores indicating higher symptom level. Results will be presented individually per week listed under time points.

    Time frame: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180

  7. Absolute change from Baseline in Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a skin disease specific questionnaire aimed at the evaluation of how the disease affects participants health related quality of life (QOL). The DLQI total score ranges from 0 to 30 with higher scores indicating higher skin disease impact on QOL. Results will be presented individually per week listed under time points.

    Time frame: Week 0, Week 16, Week 32, Week 48, Week 76, Week 92, Week 100, Week 116, Week 132, Week 148, Week 164, and Week 180

07

Study locations

145 sites
  • Hs0005 50140
    Birmingham, Alabama 35249, United States
  • Hs0005 50175
    Phoenix, Arizona 85006, United States
  • Hs0005 50162
    Fountain Valley, California 92708, United States
  • Hs0005 50161
    Los Angeles, California 90045, United States
  • Hs0005 50220
    San Diego, California 92123, United States
  • Hs0005 50196
    Thousand Oaks, California 91320, United States
  • Hs0005 50199
    Miami, Florida 33136, United States
  • Hs0005 50205
    North Miami Beach, Florida 33162-4708, United States
  • Hs0005 50152
    Orange Park, Florida 32073, United States
  • Hs0005 50184
    Pembroke Pines, Florida 33028, United States
  • Hs0005 50193
    Sandy Springs, Georgia 30329, United States
  • Hs0005 50280
    Watkinsville, Georgia 30677, United States
  • Hs0005 50234
    Plainfield, Indiana 46168, United States
  • Hs0005 50425
    Murray, Kentucky 42071, United States
  • Hs0005 50198
    Beverly, Massachusetts 01915, United States
  • Hs0005 50146
    Boston, Massachusetts 02215, United States
  • Hs0005 50178
    Clarkston, Michigan 48346, United States
  • Hs0005 50105
    St Louis, Missouri 63110, United States
  • Hs0005 50194
    Omaha, Nebraska 68144, United States
  • Hs0005 50208
    Las Vegas, Nevada 89148, United States
  • Hs0005 50159
    Newington, New Hampshire 03801, United States
  • Hs0005 50137
    East Windsor, New Jersey 08520, United States
  • Hs0005 50200
    Verona, New Jersey 07044, United States
  • Hs0005 50237
    Albuquerque, New Mexico 87102, United States
  • Hs0005 50235
    New York, New York 10003, United States
  • Hs0005 50151
    Chapel Hill, North Carolina 27516, United States
  • Hs0005 50211
    Durham, North Carolina 27710, United States
  • Hs0005 50179
    Winston-Salem, North Carolina 27157, United States
  • Hs0005 50177
    Cincinnati, Ohio 45219, United States
  • Hs0005 50138
    Columbus, Ohio 43213, United States
  • Hs0005 50145
    Columbus, Ohio 43230, United States
  • Hs0005 50202
    Fairborn, Ohio 45324, United States
  • Hs0005 50204
    Tulsa, Oklahoma 74137, United States
  • Hs0005 50147
    Hershey, Pennsylvania 17033, United States
  • Hs0005 50008
    Johnston, Rhode Island 02919, United States
  • Hs0005 50180
    Providence, Rhode Island 02903, United States
  • Hs0005 50084
    Charleston, South Carolina 29425, United States
  • Hs0005 50236
    Greenville, South Carolina 29615, United States
  • Hs0005 50142
    Nashville, Tennessee 37215, United States
  • Hs0005 50201
    Arlington, Texas 76011, United States
  • Hs0005 50148
    Pflugerville, Texas 78660, United States
  • Hs0005 50141
    Salt Lake City, Utah 84107, United States
  • Hs0005 50270
    Seattle, Washington 98101, United States
  • Hs0005 30015
    Campbelltown, Australia
  • Hs0005 30016
    Carlton, Australia
  • Hs0005 30011
    East Melbourne, Australia
  • Hs0005 30017
    Kogarah, Australia
  • Hs0005 30018
    Parkville, Australia
  • Hs0005 30014
    St Leonards, Australia
  • Hs0005 30009
    Westmead, Australia
  • Hs0005 30012
    Woolloongabba, Australia
  • Hs0005 40002
    Leuven, Belgium
  • Hs0005 40121
    Woluwe-Saint-Lambert, Belgium
  • Hs0005 40313
    Pleven, Bulgaria
  • Hs0005 40284
    Sofia, Bulgaria
  • Hs0005 40311
    Sofia, Bulgaria
  • Hs0005 40314
    Sofia, Bulgaria
  • Hs0005 40315
    Sofia, Bulgaria
  • Hs0005 40353
    Stara Zagora, Bulgaria
  • Hs0005 50233
    Barrie, Canada
  • Hs0005 50172
    Cobourg, Canada
  • Hs0005 50135
    Edmonton, Canada
  • Hs0005 50174
    London, Canada
  • Hs0005 50190
    Richmond Hill, Canada
  • Hs0005 50192
    Saskatoon, Canada
  • Hs0005 50133
    Surrey, Canada
  • Hs0005 50134
    Waterloo, Canada
  • Hs0005 50136
    Winnipeg, Canada
  • Hs0005 40063
    Prague, Czechia
  • Hs0005 40194
    Prague, Czechia
  • Hs0005 40197
    Amiens, France
  • Hs0005 40245
    Antony, France
  • Hs0005 40321
    Auxerre, France
  • Hs0005 40320
    La Rochelle, France
  • Hs0005 40355
    Le Mans, France
  • Hs0005 40247
    Lyon, France
  • Hs0005 40130
    Marseille, France
  • Hs0005 40132
    Nice, France
  • Hs0005 40404
    Reims, France
  • Hs0005 40318
    Rouen, France
  • Hs0005 40403
    Saint-Etienne, France
  • Hs0005 40246
    Saint-Mandé, France
  • Hs0005 40285
    Toulon, France
  • Hs0005 40286
    Toulouse, France
  • Hs0005 40325
    Berlin, Germany
  • Hs0005 40326
    Berlin, Germany
  • Hs0005 40248
    Bochum, Germany
  • Hs0005 40327
    Bonn, Germany
  • Hs0005 40288
    Darmstadt, Germany
  • Hs0005 40324
    Dresden, Germany
  • Hs0005 40356
    Dresden, Germany
  • Hs0005 40287
    Frankfurt am Main, Germany
  • Hs0005 40142
    Hamburg, Germany
  • Hs0005 40328
    Hanover, Germany
  • Hs0005 40249
    Kiel, Germany
  • Hs0005 40250
    Lübeck, Germany
  • Hs0005 40174
    Mainz, Germany
  • Hs0005 40323
    München, Germany
  • Hs0005 40177
    Münster, Germany
  • Hs0005 40251
    Athens, Greece

Showing the first 100 of 145 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15. PubMed 41248770 ↗
  • Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print. PubMed 42525209 ↗
  • Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available. PubMed 42482599 ↗
  • Skrzypczak T, Skrzypczak A, Matusiak L, Szepietowski JC. An evaluation of bimekizumab for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2025 Aug;25(8):811-819. doi: 10.1080/14712598.2025.2522119. Epub 2025 Jun 21. PubMed 40524676 ↗

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Jul 2026, 61 months.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2021
First posted
May 25, 2021
StartActual
May 27, 2021
Primary completionActual
Jul 22, 2026
CompletionActual
Jul 22, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
Results publication added: Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis… PubMed 42482599 ↗
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Publications Results publication added: Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis… PubMed 42482599 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04901195
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
May 25, 2021
Start date
May 27, 2021
Primary completion
Jul 22, 2026
Completion
Jul 22, 2026
Last update
Oct 6, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion